

Alexander Y Walley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6299517/publications.pdf>

Version: 2024-02-01

150
papers

6,987
citations

81900
39
h-index

66911
78
g-index

151
all docs

151
docs citations

151
times ranked

4798
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacistsâ€™ experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 157-166.	1.5	6
2	Predicting longitudinal service use for individuals with substance use disorders: A latent profile analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108632.	2.8	7
3	Warrant checking practices by post-overdose outreach programs in Massachusetts: A mixed-methods study. <i>International Journal of Drug Policy</i> , 2022, 100, 103483.	3.3	12
4	“No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108655.	2.8	20
5	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109190.	3.2	8
6	Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	3.3	8
7	Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109259.	3.2	7
8	A collaborative care intervention to improve opioid prescribing among providers caring for persons with HIV: Impact on satisfaction, confidence, and trust. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109250.	3.2	0
9	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. <i>Medical Care</i> , 2022, 60, 256-263.	2.4	15
10	Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e210-e218.	10.0	33
11	Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. <i>Health Affairs</i> , 2022, 41, 434-444.	5.2	9
12	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	3.3	3
13	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphineâ€“naloxone treatment at syringe service programs. <i>Addiction</i> , 2022, , .	3.3	4
14	Federal Policymakers Should Urgently and Greatly Expand Naloxone Access. <i>American Journal of Public Health</i> , 2022, 112, 558-561.	2.7	5
15	If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. <i>BMC Public Health</i> , 2022, 22, 735.	2.9	3
16	Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 546-552.	2.1	5
17	Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e2052-e2058.	5.8	18
18	Against Medical Advice Discharges in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2484-e2492.	5.8	32

#	ARTICLE	IF	CITATIONS
19	Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 507-515.	1.2	10
20	Age-based preferences for risk communication in the fentanyl era: “A lot of people keep seeing other people die and that's not enough for them”. <i>Addiction</i> , 2021, 116, 1495-1504.	3.3	14
21	Emergency Department Utilization Among People Living With HIV on Chronic Opioid Therapy. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110109.	1.5	1
22	Characteristics of post-overdose public health-public safety outreach in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108499.	3.2	14
23	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
24	Treatment of Refractory Opioid Use Disorder. <i>Journal of General Internal Medicine</i> , 2021, 36, 1793-1793.	2.6	1
25	Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose”. <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108313.	2.8	14
26	Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. <i>Drug and Alcohol Dependence</i> , 2021, 224, 108703.	3.2	13
27	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	3.2	25
28	Integrating substance use care into primary care for adolescents and young adults: Lessons learned. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108376.	2.8	6
29	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	3.3	13
30	“It could potentially be dangerous... but nothing else has seemed to help me.” Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108455.	2.8	4
31	Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. <i>International Journal of Drug Policy</i> , 2021, 98, 103400.	3.3	10
32	Rejection of Patients With Opioid Use Disorder Referred for Post-acute Medical Care Before and After an Anti-discrimination Settlement in Massachusetts. <i>Journal of Addiction Medicine</i> , 2021, 15, 20-26.	2.6	38
33	Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. <i>Aids</i> , 2021, 35, 697-700.	2.2	1
34	Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug “ and Non “Injection Drug “ Associated Endocarditis. <i>Clinical Infectious Diseases</i> , 2020, 71, 480-487.	5.8	8
35	Public restrooms and the opioid epidemic. <i>Substance Abuse</i> , 2020, 41, 432-436.	2.3	12
36	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. <i>International Journal of Drug Policy</i> , 2020, 85, 102602.	3.3	16

#	ARTICLE	IF	CITATIONS
37	Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. <i>Annals of Emergency Medicine</i> , 2020, 75, 29-38.	0.6	29
38	Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 304-310.	1.5	8
39	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.2	50
40	Assessing pharmacy-based naloxone access using an innovative purchase trial methodology. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 853-860.	1.5	18
41	Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waived prescriber supply. <i>Journal of Substance Abuse Treatment</i> , 2020, 115, 108032.	2.8	21
42	Response to Letter to the Editor: The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. <i>Public Health Reports</i> , 2020, 135, 542-543.	2.5	1
43	In reply:. <i>Annals of Emergency Medicine</i> , 2020, 75, 553-554.	0.6	0
44	Inpatient addiction consultation and post-discharge 30-day acute care utilization. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108081.	3.2	16
45	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	2.8	13
46	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
47	Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 740-749.	1.5	17
48	Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use—Associated Infective Endocarditis. <i>JAMA Network Open</i> , 2020, 3, e2016228.	5.9	65
49	Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 2418-2426.	2.6	9
50	Alcohol and Bone Turnover Markers among People Living with HIV and Substance Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 992-1000.	2.4	2
51	Association between mortality rates and medication and residential treatment after inpatient medically managed opioid withdrawal: a cohort analysis. <i>Addiction</i> , 2020, 115, 1496-1508.	3.3	36
52	Pharmacy leaders'™ beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1493-1497.	3.0	9
53	Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. <i>Addiction</i> , 2020, 115, 924-932.	3.3	46
54	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	5.9	17

#	ARTICLE	IF	CITATIONS
55	Chronic Opioid Therapy in People Living With Human Immunodeficiency Virus: Patients' Perspectives on Risks, Monitoring, and Guidelines. <i>Clinical Infectious Diseases</i> , 2019, 68, 291-297.	5.8	19
56	Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study – a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. <i>HIV Research and Clinical Practice</i> , 2019, 20, 48-63.	1.1	18
57	Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs. <i>Substance Abuse</i> , 2019, 40, 441-443.	2.3	16
58	Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 824-831.	1.5	16
59	The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. <i>Public Health Reports</i> , 2019, 134, 667-674.	2.5	27
60	A scoping review of post opioid-overdose interventions. <i>Preventive Medicine</i> , 2019, 128, 105813.	3.4	54
61	Touchpoints – Opportunities to predict and prevent opioid overdose: A cohort study. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107537.	3.2	113
62	Which patients receive an addiction consult? A preliminary analysis of the INREACH (INpatient) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4635-42.	2.8	10
63	Factors associated with help seeking by community responders trained in overdose prevention and naloxone administration in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107531.	3.2	18
64	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. <i>Drug and Alcohol Dependence</i> , 2019, 200, 59-63.	3.2	103
65	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	3.2	113
66	Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 5.	2.6	28
67	Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose. <i>Journal of Urban Health</i> , 2019, 96, 367-378.	3.6	40
68	Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. <i>International Journal of Drug Policy</i> , 2019, 68, 37-45.	3.3	43
69	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Mortality. <i>Annals of Internal Medicine</i> , 2019, 170, 430.	3.9	20
70	Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome. <i>Hospital Pediatrics</i> , 2019, 9, 576-584.	1.3	8
71	Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 195-201.	2.1	9
72	A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care. <i>Aids</i> , 2019, 33, 1467-1476.	2.2	16

#	ARTICLE	IF	CITATIONS
73	Effect of Age on Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011 to 2015. Journal of the American Geriatrics Society, 2019, 67, 128-132.	2.6	33
74	Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1140-1144.	1.2	13
75	Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012–2014. Drug and Alcohol Dependence, 2019, 194, 28-31.	3.2	30
76	SUN-540 No Effect Of Alcohol Use On Bone Microarchitecture Of The Distal Radius Among HIV Infected Adults. Journal of the Endocrine Society, 2019, 3, .	0.2	0
77	Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. International Journal of Drug Policy, 2018, 54, 43-50.	3.3	64
78	Expanding access to naloxone for family members: The Massachusetts experience. Drug and Alcohol Review, 2018, 37, 480-486.	2.1	30
79	Massachusetts Health Reform's Effect on Hospitalizations with Substance Use Disorder–Related Diagnoses. Health Services Research, 2018, 53, 1727-1744.	2.0	2
80	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 2018, 85, 90-96.	2.8	233
81	Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 150-159.	1.2	19
82	Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Obstetrics and Gynecology, 2018, 132, 466-474.	2.4	209
83	Frequency and associated risk factors of non-fatal overdose reported by pregnant women with opioid use disorder. Addiction Science & Clinical Practice, 2018, 13, 26.	2.6	8
84	Opioid and cocaine use among primary care patients on buprenorphine—Self-report and urine drug tests. Drug and Alcohol Dependence, 2018, 192, 245-249.	3.2	13
85	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. American Journal of Public Health, 2018, 108, 1675-1681.	2.7	109
86	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. Annals of Internal Medicine, 2018, 169, 137.	3.9	680
87	Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study. Alcoholism: Clinical and Experimental Research, 2018, 42, 1518-1529.	2.4	13
88	Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011–2015. Journal of General Internal Medicine, 2018, 33, 1512-1519.	2.6	51
89	Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. Addiction Science & Clinical Practice, 2017, 12, 4.	2.6	121
90	Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S19-S27.e4.	1.5	116

#	ARTICLE	IF	CITATIONS
91	Identification of non-steroidal anti-inflammatory drug use disorder: A case report. Addictive Behaviors, 2017, 70, 61-64.	3.0	13
92	Addiction consultation services â€“ Linking hospitalized patients to outpatient addiction treatment. Journal of Substance Abuse Treatment, 2017, 79, 1-5.	2.8	161
93	HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1129-1136.	1.2	41
94	HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. AIDS and Behavior, 2017, 21, 2618-2627.	2.7	12
95	Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. International Journal of Drug Policy, 2017, 39, 114-120.	3.3	6
96	Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. Journal of Substance Abuse Treatment, 2017, 81, 1-10.	2.8	13
97	The Surgeon General's Facing Addiction report: An historic document for health care. Substance Abuse, 2017, 38, 122-122.	2.3	7
98	Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. International Journal of Drug Policy, 2017, 46, 172-179.	3.3	225
99	Characteristics of Fentanyl Overdose â€” Massachusetts, 2014â€”2016. Morbidity and Mortality Weekly Report, 2017, 66, 382-386.	15.1	219
100	Sexual violence from police and HIV risk behaviours among HIVâ€”positive women who inject drugs in St. Petersburg, Russiaâ€”A mixed methods study. Journal of the International AIDS Society, 2016, 19, 20877.	3.0	21
101	Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. BMC Research Notes, 2016, 9, 465.	1.4	49
102	Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia. PLoS ONE, 2016, 11, e0166539.	2.5	12
103	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. Postgraduate Medical Journal, 2016, 92, 356-363.	1.8	22
104	Comments on Strang et al. (2016): â€”Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?â€”™. Addiction, 2016, 111, 1879-1880.	3.3	1
105	Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014. Public Health Reports, 2016, 131, 671-675.	2.5	23
106	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. Journal of Addiction Medicine, 2016, 10, 300-308.	2.6	57
107	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. Journal of Law, Medicine and Ethics, 2015, 43, 19-22.	0.9	19
108	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduction Journal, 2015, 12, 25.	3.2	90

#	ARTICLE	IF	CITATIONS
109	Opioid Education and Nasal Naloxone Rescue Kits in the Emergency Department. Western Journal of Emergency Medicine, 2015, 16, 381-384.	1.1	116
110	Intranasal Naloxone for Opioid Overdose Reversal. Prehospital Emergency Care, 2015, 19, 135-137.	1.8	3
111	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. AIDS and Behavior, 2015, 19, 1089-1097.	2.7	9
112	Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection. Journal of Substance Abuse Treatment, 2015, 59, 59-66.	2.8	37
113	Overdose Education and Naloxone Rescue Kits for Family Members of Individuals who Use Opioids: Characteristics, Motivations, and Naloxone Use. Substance Abuse, 2015, 36, 149-154.	2.3	41
114	A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming into Clinical Practice. Substance Abuse, 2015, 36, 240-253.	2.3	148
115	HIV prevention and treatment strategies can help address the overdose crisis. Preventive Medicine, 2015, 80, 37-40.	3.4	4
116	<scp>HERMITAGE</scp>â€”a randomized controlled trial to reduce sexually transmitted infections and <scp>HIV</scp> risk behaviors among <scp>HIV</scp>â€”infected <scp>R</scp>ussian drinkers. Addiction, 2015, 110, 80-90.	3.3	35
117	Punitive policing and associated substance use risks among HIVâ€”positive people in Russia who inject drugs. Journal of the International AIDS Society, 2014, 17, 19043.	3.0	37
118	Patient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment. AIDS Patient Care and STDs, 2014, 28, 71-81.	2.5	66
119	Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. American Journal of Epidemiology, 2014, 180, 673-686.	3.4	137
120	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. Academic Emergency Medicine, 2014, 21, 1173-1177.	1.8	73
121	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. Journal of Addiction Medicine, 2014, 8, 164-169.	2.6	5
122	Postpartum changes in methadone maintenance dose. Journal of Substance Abuse Treatment, 2014, 47, 229-232.	2.8	16
123	Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1013-1018.	1.2	11
124	Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health, 2014, 14, 297.	2.9	125
125	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. American Journal of Public Health, 2014, 104, e7-e9.	2.7	125
126	2012 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice, 2013, 8, 6.	2.6	4

#	ARTICLE	IF	CITATIONS
127	Preventing Prescription Opioid Overdose Deaths. Journal of General Internal Medicine, 2013, 28, 1258-1259.	2.6	2
128	2013 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice, 2013, 8, 18.	2.6	3
129	Opioid overdose prevention with intranasal naloxone among people who take methadone. Journal of Substance Abuse Treatment, 2013, 44, 241-247.	2.8	91
130	Nondisclosure of HIV Infection to Sex Partners and Alcohol's Role: A Russian Experience. AIDS and Behavior, 2013, 17, 390-398.	2.7	20
131	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. Drug and Alcohol Dependence, 2013, 132, 74-80.	3.2	20
132	Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ, The, 2013, 346, f174-f174.	6.0	734
133	Opioid Overdose Fatality Prevention—Reply. JAMA - Journal of the American Medical Association, 2013, 309, 873.	7.4	1
134	Methadone Dose, Take Home Status, and Hospital Admission Among Methadone Maintenance Patients. Journal of Addiction Medicine, 2012, 6, 186-190.	2.6	33
135	Sexually transmitted infections among HIV-infected heavy drinkers in St Petersburg, Russia. International Journal of STD and AIDS, 2012, 23, 853-858.	1.1	12
136	Acute Care Hospital Utilization Among Medical Inpatients Discharged With a Substance Use Disorder Diagnosis. Journal of Addiction Medicine, 2012, 6, 50-56.	2.6	115
137	Prevention of Fatal Opioid Overdose. JAMA - Journal of the American Medical Association, 2012, 308, 1863.	7.4	88
138	Integration of substance use treatment and medical care: A special issue of JSAT. Journal of Substance Abuse Treatment, 2012, 43, 377-381.	2.8	9
139	Update in Addiction Medicine for the Generalist. Journal of General Internal Medicine, 2011, 26, 77-82.	2.6	7
140	Are Opioid Dependence and Methadone Maintenance Treatment (MMT) Documented in the Medical Record? A Patient Safety Issue. Journal of General Internal Medicine, 2009, 24, 1007-1011.	2.6	15
141	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug and Alcohol Dependence, 2009, 101, 101-106.	3.2	57
142	Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose. American Journal of Public Health, 2009, 99, 788-791.	2.7	211
143	Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers. Journal of General Internal Medicine, 2008, 23, 1393-1398.	2.6	192
144	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. AIDS and Behavior, 2008, 12, 662-669.	2.7	11

#	ARTICLE	IF	CITATIONS
145	[Commentary] CAN ONE BE AN EXPERT IN ADDICTION MEDICINE WITHOUT EXPERTISE IN PAIN MANAGEMENT?. Addiction, 2008, 103, 2006-2007.	3.3	4
146	The Patients in Recovery (PIR) Perspective: Teaching Physicians about Methamphetamine. Substance Abuse, 2008, 29, 61-64.	2.3	2
147	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. Aids, 2008, 22, 415-420.	2.2	43
148	Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 2005, 28, 181-187.	2.8	70
149	Older, hypertensive, and hypercholesterolemic fairgoers visit more booths and differ in their health concerns at a community health fair. Journal of Community Health, 2000, 25, 315-329.	3.8	10
150	Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications. AIDS and Behavior, 0, , .	2.7	0